Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) generates news across respiratory support, blood monitoring, and emerging diagnostics, reflecting its role as a commercial-stage medical device company. Company announcements highlight the FDA-cleared INSPIRA ART100 cardiopulmonary support system, the development of the INSPIRA ART500 oxygenation platform, and progress with the HYLA non-invasive blood sensor, including completion of a clinical study and preparation for regulatory submission.
News coverage also follows Inspira’s strategic move into liquid biopsy diagnostics. The company has outlined a non-binding term sheet and proposed transaction to acquire an advanced liquid biopsy platform focused initially on breast cancer and circulating tumor cell analysis, alongside a concurrent equity investment and a contingent value rights framework for existing shareholders. These updates provide insight into how Inspira aims to extend its expertise in blood-based technologies into oncology diagnostics.
Investors and observers can expect IINN news to include regulatory milestones, such as submissions and anticipated approvals in markets like the United Arab Emirates, as well as updates on binding purchase orders, deployment timelines, and collaborations. Recent items have covered a registered direct offering, a Standby Equity Purchase Agreement, expansion of laboratory infrastructure, and an AI-based training alliance with Bites Learning Ltd. Leadership appointments and shareholder meeting notices also appear in the company’s news flow.
This news page aggregates these developments in one place, helping readers follow Inspira’s clinical, regulatory, commercial, and corporate updates over time.
Inspira (NASDAQ: IINN, IINNW) received a Nasdaq notice dated Feb 19, 2026, that it is not in compliance with Listing Rule 5550(b)(2) requiring a minimum market value of publicly held shares of $35,000,000.
The company has a 180-day cure period through Aug 18, 2026, to regain compliance by closing at or above $35,000,000 for 10 consecutive business days; trading of ordinary shares continues on Nasdaq.
Inspira Technologies (NASDAQ: IINN, IINNW) deployed its FDA-cleared ART100 system at a leading New York academic medical center ranked in the state top 10. The system was integrated into clinical workflow to begin a structured commercial evaluation aimed at defining protocols and wider institutional adoption.
This deployment expands Inspira's presence in Tier-1 U.S. hospitals and supports the company's ongoing U.S. commercial strategy and evaluations at other major healthcare facilities.
Inspira Technologies (NASDAQ: IINN) will showcase its FDA-cleared ART100 at AmSECT 64th International Conference, March 25–29, 2026, in Austin, Texas, via U.S. distributor Glo-Med Networks.
The company is targeting perfusionists and cardiac surgical teams to accelerate U.S. commercial adoption, leveraging its FDA 510(k) clearance (May 2024) and active distribution channel for clinical integration.
Inspira Technologies (NASDAQ: IINN) received a Nasdaq written notification on Feb 9, 2026, for failing to meet the $1.00 minimum bid price under Nasdaq Listing Rule 5550(a)(2).
The company has a 180-calendar-day compliance period until Aug 10, 2026, to regain compliance by achieving a $1.00 closing bid for ten consecutive business days; shares continue to trade on Nasdaq during this period.
Inspira Technologies (NASDAQ: IINN) secured vendor approval from the Medical Equipment Committee of Clalit Health Services, enabling immediate procurement and deployment of the INSPIRA ART100 across Clalit's network serving approximately 4.9 million members.
The approval covers 14 major hospitals and over 1,600 clinics, follows a technical and clinical review by the relevant professional committee, and positions the ART100 for commercial use within one of the world’s largest integrated HMOs.
Inspira (NASDAQ: IINN, IINNW) priced a registered direct offering of 6,785,715 ordinary shares at $0.70 per share, expected to raise approximately $4.75 million gross, plus a concurrent private placement of unregistered warrants to purchase up to 6,785,715 shares.
The warrants have an exercise price of $0.70, become exercisable six months after issuance, and expire 5.5 years from issuance. Closing is expected on or about February 6, 2026. The company also agreed to amend certain existing warrants to a $0.70 exercise price.
Inspira Technologies (NASDAQ: IINN) validated its Next-Generation Standalone HYLA blood sensor, reporting 94.2% accuracy for continuous pCO₂ measurement concordant within a 7 mmHg threshold. The standalone configuration targets an immediate commercial pathway into the ~$48 billion heart-lung surgery market and plans a U.S. FDA submission in 2026. The strategy emphasizes disposable optical sensors and modular software for recurring revenue and broader OR/ICU integration.
Inspira Technologies (NASDAQ: IINN) announced its FDA-cleared INSPIRA ART100 completed full clinical evaluation and moved from pilot use to routine workflow at a top U.S. academic medical center.
Approximately 30 patients were treated across multiple indications and the hospital has begun a budgeted procurement process for multiple ART100 systems.
Inspira (NASDAQ: IINN) said two previously announced binding purchase orders — $22.5 million (July 2, 2025) and $27 million (August 19, 2025) — have advanced to the final budgetary validation and fund allocation stage within relevant governmental procurement processes.
The company reported that ~91% of the orders have cleared commercial and administrative review and are undergoing the concluding budgetary authorization step prior to fund release and execution. Inspira expects payment and revenue recognition during the 2026 fiscal cycle, subject to customary governmental approvals, and says internal execution preparations are complete.
Inspira (NASDAQ: IINN) outlined a strategic vision and a proposed transaction framework to expand into liquid biopsy diagnostics through a contemplated acquisition of an advanced liquid biopsy platform and a concurrent equity investment. The company says the structure is designed to preserve shareholder value, enable future dividend distributions from its core respiratory and life-support technologies, and allocate value via a CVR framework. Inspira highlights its HYLA blood sensor (clinical accuracy reported at 95%–99% across measured parameters), an established blood diagnostics laboratory, and prior FDA 510(k) clearance of the ART100 system as foundations to accelerate regulatory and commercial progress for the new platform.